Breast Cancer

A Curated Room: The People Shaping Practice

Now in its third year, this invitation-only meeting convenes a deliberately small faculty: 24 leading breast oncology KOLs alongside 24 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.

The science tracks where treatment is moving: antibody-drug conjugates in HER2-positive and triple-negative disease, biomarker-driven selection after CDK4/6 progression, chemoimmunotherapy in early stage TNBC, and emerging mechanisms in rare histologies. Every session pairs expert talks with a moderated panel discussion, sustained, close-quarters engagement rather than a lecture hall.